In conclusion, this study demonstrates that STARD4 enhances HCC growth and lenvatinib resistance by regulating cholesterol homeostasis and activating the EGFR/PI3K/AKT pathway. This evidence concerns the gene STARD4 and hepatocellular carcinoma.